Allurion Seeks Option Repricing, Reverse Split Amid Capital Structure Overhaul

TL;DR

**Allurion's proposed option repricing and aggressive reverse stock split are red flags, signaling a desperate attempt to prop up a struggling stock and retain executives at shareholder expense.**

AI Summary

Allurion Technologies, Inc. (ALURW) is holding its annual meeting on December 18, 2025, to address several critical proposals impacting its capital structure and employee incentives. Key proposals include the election of three Class II Directors (Dr. Omar Ishrak, R. Jason Richey, and Douglas Hudson) and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2025. Financially, the company seeks approval for a significant amendment to its 2023 Stock Option and Incentive Plan, increasing authorized shares and extending its term. Crucially, Allurion proposes repricing certain outstanding stock options, which would benefit named executive officers like CEO Shantanu Gaur (57,144 shares at $57.50 weighted average exercise price) and COO Ojas Buch (12,271 shares at $35.75 weighted average exercise price). The company also requests approval for issuing common stock upon conversion of Series B convertible preferred stock and exercise of private placement warrants, both to comply with NYSE Listing Rule 312.03. Finally, a reverse stock split proposal, with a ratio between 1-for-1.5 and 1-for-20, aims to consolidate outstanding shares, likely to address potential delisting concerns or improve share price perception. The Board recommends voting FOR all proposals.

Why It Matters

This DEF 14A filing reveals Allurion Technologies' proactive measures to stabilize its financial standing and incentivize key personnel, directly impacting investors' equity value and employee morale. The proposed option repricing could dilute existing shareholders but is intended to retain and motivate executives like CEO Shantanu Gaur, who holds 57,144 eligible options. The reverse stock split, ranging from 1-for-1.5 to 1-for-20, is a significant move that could boost the stock price to meet NYSE listing requirements, but it also signals underlying challenges with the current share valuation. Competitively, these actions suggest Allurion is working to strengthen its position in the medical technology sector by ensuring executive alignment and maintaining market visibility.

Risk Assessment

Risk Level: high — The proposal to reprice outstanding stock options (Proposal 4) and implement a reverse stock split (Proposal 7, up to 1-for-20) indicates significant financial distress or a need to drastically improve share price to maintain listing. Repricing options, especially for executives like Shantanu Gaur (57,144 shares at $57.50) and Brendan Gibbons (10,153 shares at $74.00), can be highly dilutive and suggests previous grants are significantly underwater, reflecting poor past performance. A reverse stock split, while potentially preventing delisting, often signals a company struggling to maintain investor confidence and can lead to further price declines post-split.

Analyst Insight

Investors should carefully evaluate the potential dilution from the option repricing and the implications of a reverse stock split on their holdings. Consider voting against Proposals 3, 4, 5, 6, and 7 if you believe these measures are overly dilutive or do not adequately address the company's underlying performance issues. Monitor the stock's performance closely post-meeting for signs of sustained recovery or further decline.

Executive Compensation

Key Numbers

• 7,770,047 — shares of common stock outstanding (as of the Record Date, October 31, 2025)
• $57.50 — weighted average exercise price (of Shantanu Gaur's 57,144 eligible options)
• $74.00 — weighted average exercise price (of Brendan Gibbons' 10,153 eligible options)
• $35.75 — weighted average exercise price (of Ojas Buch's 12,271 eligible options)
• 1-for-1.5 — minimum reverse stock split ratio (proposed for common stock)
• 1-for-20 — maximum reverse stock split ratio (proposed for common stock)
• December 18, 2025 — Annual Meeting date (when proposals will be voted on)
• October 31, 2025 — Record Date (for stockholders entitled to vote)

Key Players & Entities

• Allurion Technologies, Inc. (company) — Registrant and company filing DEF 14A
• Shantanu Gaur (person) — President and Chief Executive Officer, holds 57,144 eligible options
• Brendan M. Gibbons (person) — Chief Legal and People Officer and Secretary, holds 10,153 eligible options
• Ojas Buch (person) — Chief Operating Officer, holds 12,271 eligible options
• Dr. Omar Ishrak (person) — Nominee for Class II Director
• R. Jason Richey (person) — Nominee for Class II Director
• Douglas Hudson (person) — Nominee for Class II Director
• Deloitte & Touche LLP (company) — Independent registered public accounting firm
• U.S. Securities and Exchange Commission (regulator) — Regulates proxy statement filings
• NYSE (regulator) — Listing Rule 312.03 compliance

FAQ

Risk Factors

• Reverse Stock Split for Share Price and Listing Compliance [high — financial]: The company is proposing a reverse stock split with a ratio between 1-for-1.5 and 1-for-20. This is likely to address potential delisting concerns from the NYSE or to improve the perception of its share price. Failure to maintain minimum bid price requirements could lead to delisting.
• Stock Option Repricing Impact [medium — financial]: The company seeks approval to reprice certain outstanding stock options. This action could significantly benefit executives, such as the CEO and COO, by lowering their exercise prices. The financial impact and fairness of such repricing are key considerations for shareholders.
• NYSE Listing Rule Compliance [high — regulatory]: Approval is sought for the issuance of common stock upon conversion of Series B preferred stock and exercise of private placement warrants to comply with NYSE Listing Rule 312.03. Non-compliance with listing rules can lead to delisting.
• Stock Plan Amendment and Share Increase [medium — financial]: The company proposes to amend and restate its 2023 Stock Option and Incentive Plan, including increasing the number of authorized shares. This could lead to further dilution for existing shareholders if not managed effectively.

Industry Context

Allurion Technologies operates in the medical device sector, specifically focusing on weight loss solutions. The industry is characterized by innovation, regulatory scrutiny from bodies like the FDA, and competition from various therapeutic approaches. Companies often rely on equity financing and strategic partnerships to fund research, development, and market expansion.

Regulatory Implications

The company must comply with NYSE listing rules regarding the issuance of new shares, as highlighted by Proposals 5 and 6. Failure to meet these requirements or maintain minimum share prices could lead to delisting. Additionally, the approval of stock-based compensation plans and repricing is subject to shareholder and potentially regulatory oversight.

What Investors Should Do

1. Vote FOR Proposal 1: Election of Directors to maintain experienced leadership.
2. Vote FOR Proposal 2: Ratification of Deloitte & Touche LLP to ensure audit integrity.
3. Vote FOR Proposal 3: Approval of 2023 Plan Amendment to support future equity incentives and growth.
4. Vote FOR Proposal 4: Approval of Option Repricing, considering the potential benefits to executives and impact on dilution.
5. Vote FOR Proposals 5 & 6: Approval of Stock Issuances to ensure compliance with NYSE rules and facilitate capital structure adjustments.
6. Vote FOR Proposal 7: Approval of Reverse Stock Split to address share price concerns and maintain NYSE listing.

Key Dates

• 2025-12-18: Annual Meeting of Stockholders — Date for voting on critical proposals including director elections, auditor ratification, stock plan amendments, option repricing, and reverse stock split.
• 2025-10-31: Record Date — Establishes the list of stockholders entitled to vote at the Annual Meeting.

Glossary

DEF 14A

A proxy statement filing required by the SEC for companies holding annual meetings of shareholders, detailing information about the meeting and the matters to be voted upon. (This document provides the basis for the analysis of Allurion Technologies' upcoming shareholder meeting and the proposals being presented.)

Class II Directors

Directors elected for a specific term, typically three years, forming one of the classes into which a board of directors may be divided. (Shareholders will vote on the election of three Class II Directors, impacting the company's governance.)

2023 Stock Option and Incentive Plan

A company plan that allows for the granting of stock options and other equity-based incentives to employees and directors. (The company is seeking approval to amend and restate this plan, including increasing authorized shares and extending its term, which affects equity dilution and executive compensation.)

Repricing

The process of lowering the exercise price of existing stock options, typically when the stock's market price has fallen below the original exercise price. (Allurion proposes repricing certain options, which could benefit executives but may be viewed negatively by some shareholders due to potential dilution and fairness concerns.)

Series B convertible preferred stock

A class of preferred stock that can be converted into a predetermined number of common stock shares. (The issuance of common stock upon conversion of this preferred stock requires shareholder approval to comply with NYSE rules.)

Private placement warrants

Warrants issued in a private transaction, giving the holder the right to purchase a company's stock at a specified price. (The issuance of common stock upon the exercise of these warrants requires shareholder approval to comply with NYSE rules.)

Reverse stock split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into a smaller number. (Allurion is proposing a reverse stock split to potentially increase its share price and avoid delisting from the NYSE.)

NYSE Listing Rule 312.03

A rule from the New York Stock Exchange that generally requires shareholder approval for the issuance of securities that could result in a significant dilution of existing shareholders' ownership. (The company needs shareholder approval for certain stock issuances to comply with this rule.)

Year-Over-Year Comparison

This filing is a proxy statement for the annual meeting and does not contain comparative financial data in the same way an annual report (10-K) would. However, the proposals themselves indicate significant corporate actions being considered, such as a reverse stock split and stock option repricing, suggesting potential challenges or strategic shifts since the last filing. The need for these proposals implies a review of the company's financial health and stock performance.

Key Financial Figures

• $0.0001 — er of shares of common stock, par value $0.0001 per share (the "common stock"), of the

Filing Documents

• d923025ddef14a.htm (DEF 14A) — 963KB
• g923025dsp007.jpg (GRAPHIC) — 152KB
• g923025dsp008.jpg (GRAPHIC) — 109KB
• g923025g00n04.jpg (GRAPHIC) — 63KB
• 0001193125-25-293675.txt ( ) — 2179KB
• alur-20241231.xsd (EX-101.SCH) — 3KB
• d923025ddef14a_htm.xml (XML) — 5KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 72 Certain Relationships and Related Person Transactions 74 Additional Information 82 i Table of Contents ALLURION TECHNOLOGIES, INC. 11 Huron Drive Natick, Massachusetts 01760 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD DECEMBER 18, 2025 Dear Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders (the "Annual Meeting") of Allurion Technologies, Inc., a Delaware corporation (the "Company"), will be held at 12:00 p.m. Eastern Time on December 18, 2025. The Annual Meeting will be a completely virtual meeting conducted via live audio webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/ALUR2025 and entering your 16-digit control number included on your proxy card or in the instructions that accompanied your proxy materials. You will not be able to attend the Annual Meeting in person. The Annual Meeting will be held for the following purposes: Proposal 1: To elect three Class II Directors named in the Proxy Statement to serve until the Company's 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified or until their earlier death, resignation or removal; Proposal 2: To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; Proposal 3: To approve an amendment and restatement of the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan (the "2023 Plan" and as amended and restated, the "Amended and Restated Plan") to (i) increase the number of shares of common stock, par value $0.0001 per share (the "common stock"), of the Company authorized for issuance thereunder (with a corresponding increase to the number of shares of common stock that may be issued in respect of incentiv

View Full Filing

View this DEF 14A filing on SEC EDGAR